Drugs / galiximab
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00651443 | Aug 2008 → Nov 2010 | non-Hodgkin lymphoma | Biogen | Terminated | No outcome recorded Stop: Business |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00048555 | Nov 2002 → Mar 2004 | non-Hodgkin lymphoma | Biogen | Completed | No outcome recorded |
| Phase 1/2 | NCT00575068 | Jan → Sep 2002 | B-cell non-Hodgkin lymphoma | Biogen | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00516217 | Jun 2008 → Sep 2011 | lymphoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00117975 | Jun 2005 → Jun 2007 | lymphoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00384150 | Nov 2007 → Jan 2010 | non-Hodgkin lymphoma | Biogen | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00363636 | Sep 2006 → Jan 2010 | non-Hodgkin lymphoma | Biogen | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | galiximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00117975 ↗ |
| Known as | IDEC-114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00575068 ↗ |
| Action | Inhibit | “Monoclonal antibodies, such as galiximab, can block cancer growth in different ways.” NCT00516217 ↗ |
| Modality | Monoclonal antibody | “Anti-CD80 Monoclonal Antibody” NCT00048555 ↗ |
| Route | Intravenous | “given IV” NCT00117975 ↗ |
| Target | CD80 | “Anti-CD80 Monoclonal Antibody” NCT00048555 ↗ |